Geçmişten Günümüze BCG Aşısı

Authors

Pınar Sağıroğlu

References

Lange C, Aaby P, Behr MA, ve ark. 100 years of Mycobacterium bovis bacille Calmette-Guérin. The Lancet Infectious Diseases. 2022;22(1):e2-e12.

Ahmed A, Rakshit S, Adiga V, ve ark. A century of BCG: Impact on tuberculosis control and beyond. Immunological Reviews. 2021;301(1):98-121.

Fatima S, Kumari A, Das G, ve ark. Tuberculosis vaccine: A journey from BCG to present. Life Sciences. 2020;252:117594.

Starshinova A, Kudryavtsev I, Rubinstein A, ve ark. BCG vaccination: historical role, modern applications, and future perspectives in tuberculosis and beyond. Frontiers in Pediatrics. 2025;13:1603732.

Martinez L, Cords O, Liu Q, ve ark. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. The Lancet Global Health. 2022;10(9):e1307-e1316.

Chen J, Gao L, Wu X, ve ark. BCG-induced trained immunity: history, mechanisms and potential applications. Journal of Translational Medicine. 2023;21(1):106.

Moorlag SJCFM, Arts RJW, van Crevel R, ve ark. Non-specific effects of BCG vaccine on viral infections. Clinical Microbiology and Infection. 2019;25(12):1473-1478.

Mukherjee N, Julián E, Torrelles JB, ve ark. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond. Vaccine. 2021;39(50):7332-7340.

Lobo N, Brooks NA, Zlotta AR, ve ark. 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nature Reviews Urology. 2021;18(10):611-622.

Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nature Reviews Urology. 2018;15(10):615-625.

Aslan G, Alkaya D. Yüz Yıllık Tüberküloz Aşısı: Bacille Calmette-Guérin Tarihçesi - BCG Aşısı Koruyucu Eğitilmiş Bağışıklığı Başlatabilir Mi? Turk J Immunol. 2022;10(1):12-21.

Tagliabue A, Boraschi D, Leite LCC, ve ark. 100 Years of BCG Immunization: Past, Present, and Future. Vaccines. 2022;10(10):1743.

Bukula L, Chengalroyen MD, Omollo C, ve ark. Factors influencing the efficacy of Bacille Calmette-Guérin (BCG) vaccine. The Microbe. 2025;6:100230.

Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomedicine & Pharmacotherapy. 2007;61(6):299-305.

Cardillo F, Bonfim M, Sousa PSV, ve ark. Bacillus Calmette-Guérin Immunotherapy for Cancer. Vaccines. 2021;9(5):439.

Grier AL, Zhong JY, Basourakos S, ve ark. Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer. Cancers. 2026;18(4):623.

Unsworth-White S, Kitchen M, Bryan R. Immunotherapy for non-muscle invasive bladder cancer: from the origins of BCG to novel therapies. Future Oncology. 2022;18(1):105-115.

Greenblatt CL, Lathe R. Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors. Journal of Alzheimer’s Disease. 2024;98(2):343-360.

Zhuang L, Ye Z, Li L, ve ark. Next-Generation TB Vaccines: Progress, Challenges, and Prospects. Vaccines. 2023;11(8):1304.

Zeng S, Xing S, Zhang Y, ve ark. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment. Journal of Zhejiang University-SCIENCE B. 2024;25(7):557-567.

Mouhoub E, Domenech P, Ndao M, ve ark. The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview. Frontiers in Microbiology. 2021;12:757858.

Published

November 17, 2026

License

License